Skip to main content

Table 7 Multiple Tobit regression adjusting for age and co-morbidities (left ear)

From: Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity

Frequency (Hz)

No. of non-responses

Risk factors

Estimate of coefficient (SE); p-value

HIV seropositive

NCD

LFPTT

125

1

11.59 (3.69); 0.01

2.72 (2.81); 0.33

250

0

9.59 (4.11); 0.02

2.93 (3.14); 0.35

500

0

9.66 (4.6); 0.04

3.42 (3.52); 0.33

MFPTT

1000

0

6.74 (5.05); 0.18

2.91 (3.86); 0.45

2000

0

7.65 (4.98); 0.12

2.99 (3.81); 0.43

HFPTT

4000

1

9.68 (5.36); 0.07

7.19 (4.09); 0.08

8000

0

6.5 (6.37); 0.31

2.03 (4.87); 0.68

9000

1

1.02 (5.93); 0.86

5.29 (4.51); 0.24

EHFPTT

10,000

3

0.07 (6.18); 0.99

6.73 (4.68); 0.15

11,200

5

0.90 (6.0); 0.88

2.11 (4.55); 0.64

12,500

12 (14.6%)

2.87 (5.84)0.62

− 0.68 (4.42); 0.88

14,000

23 (28%)

8.25 (6.21); 0.18

6.11 (4.72); 0.19

16,000

50 (61%)

− 1.3 (6.76); 0.85

11.35 (5.54); 0.04

18,000

68 (83%)

5.68 (12.71); 0.65

15.23 (10.54); 0.15

20,000

73 (89%)

1.75 (5.92); 0.77

5.56 (5.16); 0.28

  1. LFPTT, Low-frequency pure tone thresholds; MFPTT, Mid-frequency pure tone thresholds; HFPTT, High-frequency pure tone thresholds; EHFPTT, Extended high-frequency pure tone thresholds; NCD, Hypertension and Diabetes